Travere Therapeutics, Inc.

NasdaqGM:TVTX Stock Report

Market Cap: US$1.8b

Travere Therapeutics Valuation

Is TVTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TVTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$185.72
Fair Value
88.7% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: TVTX ($21.05) is trading below our estimate of fair value ($185.72)

Significantly Below Fair Value: TVTX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TVTX?

Key metric: As TVTX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TVTX. This is calculated by dividing TVTX's market cap by their current revenue.
What is TVTX's PS Ratio?
PS Ratio9x
SalesUS$203.45m
Market CapUS$1.78b

Price to Sales Ratio vs Peers

How does TVTX's PS Ratio compare to its peers?

The above table shows the PS ratio for TVTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.2x
NVAX Novavax
1.6x-8.0%US$1.4b
DVAX Dynavax Technologies
6.6x16.5%US$1.7b
CDNA CareDx
3.9x12.9%US$1.2b
RCUS Arcus Biosciences
4.7x26.0%US$1.2b
TVTX Travere Therapeutics
9x30.5%US$1.8b

Price-To-Sales vs Peers: TVTX is expensive based on its Price-To-Sales Ratio (9x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does TVTX's PS Ratio compare vs other companies in the US Biotechs Industry?

138 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.2x1.2%US$21.04b
MRNA Moderna
3.1x10.2%US$15.67b
INCY Incyte
3.5x5.4%US$14.20b
EXAS Exact Sciences
3.9x9.3%US$10.16b
TVTX 9.0xIndustry Avg. 10.1xNo. of Companies138PS01632486480+
138 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TVTX is good value based on its Price-To-Sales Ratio (9x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is TVTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TVTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9x
Fair PS Ratio4.3x

Price-To-Sales vs Fair Ratio: TVTX is expensive based on its Price-To-Sales Ratio (9x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TVTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$21.05
US$28.47
+35.2%
28.1%US$45.00US$18.00n/a15
Jan ’26US$17.42
US$27.40
+57.3%
30.1%US$42.00US$15.00n/a15
Dec ’25US$18.81
US$27.40
+45.7%
30.1%US$42.00US$15.00n/a15
Nov ’25US$17.57
US$26.38
+50.1%
34.1%US$43.00US$12.00n/a16
Oct ’25US$13.99
US$17.00
+21.5%
26.1%US$23.00US$9.00n/a14
Sep ’25US$9.47
US$15.36
+62.2%
23.2%US$20.00US$9.00n/a14
Aug ’25US$9.24
US$14.86
+60.8%
24.5%US$20.00US$9.00n/a14
Jul ’25US$8.28
US$14.86
+79.4%
24.5%US$20.00US$9.00n/a14
Jun ’25US$7.42
US$14.86
+100.2%
24.5%US$20.00US$9.00n/a14
May ’25US$6.00
US$14.79
+146.4%
25.3%US$21.00US$9.00n/a14
Apr ’25US$7.31
US$14.80
+102.5%
23.9%US$21.00US$9.00n/a15
Mar ’25US$7.87
US$14.80
+88.1%
23.9%US$21.00US$9.00n/a15
Feb ’25US$8.60
US$14.73
+71.3%
29.5%US$23.00US$8.00n/a15
Jan ’25US$8.99
US$14.40
+60.2%
32.8%US$23.00US$8.00US$17.4215
Dec ’24US$6.42
US$14.07
+119.1%
34.4%US$23.00US$7.00US$18.8115
Nov ’24US$6.72
US$15.43
+129.6%
34.4%US$25.00US$8.00US$17.5714
Oct ’24US$8.94
US$18.64
+108.5%
49.2%US$41.00US$8.00US$13.9914
Sep ’24US$14.87
US$26.93
+81.1%
27.5%US$41.00US$15.00US$9.4714
Aug ’24US$16.72
US$28.00
+67.5%
26.9%US$41.00US$15.00US$9.2414
Jul ’24US$15.36
US$28.29
+84.2%
26.4%US$39.00US$15.00US$8.2814
Jun ’24US$18.20
US$28.77
+58.1%
26.2%US$39.00US$15.00US$7.4213
May ’24US$22.61
US$35.08
+55.2%
26.6%US$52.00US$17.00US$6.0012
Apr ’24US$22.49
US$34.92
+55.3%
26.3%US$52.00US$17.00US$7.3112
Mar ’24US$21.74
US$35.62
+63.8%
25.7%US$52.00US$17.00US$7.8713
Feb ’24US$22.09
US$32.92
+49.0%
24.3%US$44.00US$17.00US$8.6012
Jan ’24US$21.03
US$31.83
+51.4%
23.6%US$44.00US$17.00US$8.9912
Analyst Price Target
Consensus Narrative from 15 Analysts
US$28.47
Fair Value
26.1% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 23:52
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Travere Therapeutics, Inc. is covered by 30 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guyn KimBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Gregory HarrisonBofA Global Research